Case study shows that peptide treatment can improve mobility in  older and larger breed canines (dogs)

Aging in pets gives rise to a range of symptoms that usually involve a reduction in overall mobility and also in overall activity.

The start and level of severity of these aging symptoms depend on a variety of factors, including the pet’s breed size, genetics, weight, general joint health, nutrition, environmental factors, and lifestyle, as well as normal wear and tear on joints. Aging symptoms can therefore be individual to each pet.

Improving pets’ mobility during aging is important for several reasons, including improving their quality of life and maximizing their health. All pet owners wish their pets to have the best possible health and quality of life.

Like in humans, osteoarthritis is prevalent in older canines (dogs), and the incidence and severity of osteoarthritis can really reduce the quality of life of older canines. Osteoarthritis is more prevalent in older and larger breeds of dogs, and the incidence and severity depend on the canine joints/ involved. As the aging process continues, joint damage is even more likely to continue to occur.

Currently, treatment options for osteoarthritis in canines are limited to anti-inflammatories and biologic therapies, which give relief to the canine but don’t fix the condition itself.  These treatments treat the inflammation but not the destructive underlying process in the joints. Also, biological therapies are not intended for long-term use.

There is an unmet need to safely and effectively treat or delay joint damage in older canines. At BioPep, we believe that better health is achievable through safe, scientifically tested organopeptides, which can help tissue rejuvenation in joints that are worn and damaged by aging or disease. Peptide therapy is the use of targeted signaling amino acid chains to instruct cells on the functions they need to perform.

We utilize organopeptides manufactured at the European Wellness Biomedical Group (EW)  manufacturing facility in Europe to ensure that all organopeptide products are pathogen free and safe. Our organopeptides, which are Nano Organo Peptides or Mito Organelles  (NOPs and MOs), are being used to rejuvenate and improve animal health.

In a recently published study in the Open Access Journal of Biomedical Science, our scientists have shown that our NOPs can improve joint health in canines (dogs). We hypothesized that the NOP properties of the peptides would improve joint health in canines because of their stem cell origin, which means that NOPs have anti-inflammatory effects, as well as regenerative and reparative properties. Due to these properties, NOPs offer the potential to target a vast array of diseases.

Our case study involved two 9-year-old female Shiloh Shepherds, Subjects A and B. These  Subjects underwent NOP treatments in two phases for 534 days. The treatments used were based on observations of the canines’ behaviors and symptoms. A Canine Mobility  Assessment form was then scored to assess the canines’ pain, discomfort, and mobility in managing daily activity, including slowing down on walks, playing less than usual, difficulty jumping or climbing stairs, stiffness on rising, and changes in sleeping position.

Our results showed that the general activity of the dogs was significantly improved following peptide treatment within 1-2 months following peptide administration and return to normal level of mobility at 8 months. We observed an improvement in the mobility and activity levels observed as the ability to get up from a down position, desire to play and go outside in the canines tested.

In this case study, our data demonstrated that NOP therapy was tolerated by two canine subjects and a significant improvement in their mobility and activity was observed. Though limited conclusions can be drawn, this small case study suggests that NOPs can be used to treat aging in canine joints and thus improve animal health.

Additionally, no adverse effects were observed in this case study, which suggests that these organopeptides are both safe and effective. Future studies will need to be done to increase the number of canine subjects.

At BioPep, we partner with top-tier research institutions, universities and manufacturing  facilities to provide data on the effectiveness of organ-specific peptides’ ability to rejuvenate and heal. This promising study could also pave the way for peptide therapy research in the joint health in other mammals beyond canines.

Augusta Wellington, Jonathan R. T. Lakey, Alana Williams, Mike M.K. Chan, Michelle B. F.  Wong, Marcelle Gisain, Caroline Mosessain, Orn Adalsteinsson, Desiree C.T. Cox, ‘Peptide  Therapy Improves Mobility in Older and Large Breed Canines: A Case Study”, Open Access  Journal of Biomedical Science (OAJBS), 2022. In Press

Similar Posts